Incyte Corporation ($INCY) Stock Forecast: Up 6.2% Today

What is Incyte Corporation?

Incyte Corporation (NASDAQ: INCY) Market Incyte Corporation operates in the biopharmaceutical industry, focusing on innovation in Hematology, Oncology, and Inflammation and Autoimmunity. Notable products from the company include Jakafi and Opzelura, alongside a robust pipeline across various therapeutic areas.

Why is Incyte Corporation going up?

INCY stock is up 6.2% on Apr 29, 2026 13:50

• Bullish Movement: The recent notable uptrend in Incyte Corporation's stock price is a result of its strong Q1 2026 financial performance and optimistic projections for future expansion.
• Earnings Beat: Incyte reported a remarkable 20% year-over-year growth in net sales, propelled by strong product demand and significant progress in its pipeline, particularly evident through successful regulatory submissions and favorable trial outcomes.
• Investor Confidence: The company's disclosure of upcoming participation in investor conferences during May has contributed to enhancing investor trust in its strategic vision and dedication to sustained growth.
• Market Positioning: Despite facing competition in the market and the necessity for pipeline successes, Incyte's solid financial results and diverse product portfolio point towards a bright future outlook concerning its growth trajectory and market status.

INCY Price Chart

INCY Technical Analysis

INCY News

Incyte Corporation (NASDAQ:INCY) Q1 2026 Earnings Call Transcript

Incyte Corporation (NASDAQ: INCY) reported strong Q1 2026 earnings, with net sales up 20% year-over-year, driven by robust demand across its portfolio including Jakafi and Opzelura. The company highlighted significant pipeline advancements, including regulatory submissions for povorcitinib in hidradenitis suppurativa and positive Phase III results for povorcitinib in nonsegmental vitiligo, positioning Incyte for growth beyond its cornerstone product, Jakafi. Strategic leadership appointments and a focus on expanding its hematology, oncology, and immunology franchises underscore the company's commitment to long-term growth and market diversification.

https://www.insidermonkey.com/blog/incyte-corporation-nasdaqincy-q1-2026-earnings-call-transcript-1749912/

Two May Incyte conference presentations will stream live online

Incyte (Nasdaq: INCY) announced it will present at two investor conferences in May: the BofA Securities 2026 Health Care Conference on May 13th and the RBC 2026 Global Healthcare Conference on May 19th. Both presentations will be webcast live on Investor.Incyte.com and available for replay for 30 days. Incyte focuses on biopharmaceutical innovation in Hematology, Oncology, and Inflammation and Autoimmunity.

https://www.stocktitan.net/news/INCY/incyte-to-present-at-upcoming-investor-5se73z3413g4.html

Incyte Corp (INCY) Q1 2026 Earnings Call Highlights: Strong Reve

Incyte Corp (INCY) reported a strong start to 2026 with a 21% increase in total revenue, reaching $1.27 billion, and an 18% rise in R&D expenses as it advances its late-stage pipeline. The company is strategically diversifying its portfolio beyond its cornerstone product, Jakafi, with promising developments in povorcitinib for hidradenitis suppurativa and nonsegmental vitiligo, and other oncology and immunology trials. Despite challenges in market competition and sustained reliance on pipeline success, Incyte maintains a positive outlook with increased full-year sales guidance for its key products.

https://www.gurufocus.com/news/8825792/incyte-corp-incy-q1-2026-earnings-call-highlights-strong-revenue-growth-and-promising-pipeline-developments

Earnings To Watch: Amgen (AMGN) Reports Q1 Results Tomorrow

Biotech company Amgen (NASDAQ:AMGN) is set to report its Q1 earnings, with market expectations for a 4.3% year-on-year revenue growth. Amgen beat revenue expectations last quarter with an 8.6% increase, and analysts have recently become more bullish on its revenue estimates. Despite positive sentiment in the broader biotechnology segment, Amgen's stock is down 2.9% over the last month.

https://www.theglobeandmail.com/investing/markets/stocks/AMGN/pressreleases/1576250/earnings-to-watch-amgen-amgn-reports-q1-results-tomorrow/

Incyte Corporation 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:INCY) 2026-04-28

Incyte Corporation (NASDAQ: INCY) reported strong financial results for Q1 2026, with an EPS of $1.81, beating estimates by $0.47, and revenue of $1.27 billion, exceeding expectations by $61.42 million and representing a 20.87% year-over-year increase. The company published a slide deck in conjunction with their earnings call to provide further details on these results.

https://seekingalpha.com/article/4895458-incyte-corporation-2026-q1-results-earnings-call-presentation

Trending Today

Natural Gas ($GAS) Commodity Forecast: Up 5.0% Today

Silver ($XAG) Commodity Forecast: Up 6.8% Today

Perrigo Company plc ($PRGO) Stock Forecast: Down 5.0% Today

CF Industries Holdings Inc. ($CF) Stock Forecast: Up 5.6% Today

Airbnb Inc. ($ABNB) Stock Forecast: Down 5.1% Today

AMC Entertainment Holdings Inc. Class A ($AMC) Stock Forecast: Down 5.2% Today

Zebra Technologies Corporation ($ZBRA) Stock Forecast: Down 5.1% Today

Trimble Inc. ($TRMB) Stock Forecast: Down 5.1% Today

Booking Holdings Inc. ($BKNG) Stock Forecast: Down 5.0% Today

Zoetis Inc. Class A ($ZTS) Stock Forecast: Down 5.3% Today

Incyte Corporation Price History

07.00.2026 - INCY Stock was up 5.8%

• INCY is the ticker symbol for Incyte, a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The overall market today saw bullish movements, with the Dow and S&P 500 hitting record highs.
• ASSESSMENT:
• The bullish movement in INCY today can be attributed to the positive top-line results from its Phase III frontMIND study for Monjuvi/Minjuvi in combination with Bristol Myers’ Revlimid and R-CHOP for newly diagnosed DLBCL. This successful study meeting key goals and endpoints has likely boosted investor confidence in the company's pipeline and future prospects.
• Additionally, the exclusive license agreement with Prelude Therapeutics for the advanced clinical development of PRT2527 for oncology showcases strategic collaborations that can enhance the company's position in the market and expand its potential for growth.
• The upcoming submission of a supplemental biologics license application to the FDA for label expansion for first-line DLBCL treatment further indicates positive developments in the company's product portfolio, potentially attracting more investors seeking exposure to innovative treatments in the biopharmaceutical sector.

28.03.2026 - INCY Stock was up 1.3%

• Despite exceeding first-quarter earnings and revenue expectations, Incyte Corporation's stock saw a 4% decrease in pre-market trading.
• The stock decline is linked to the company's lower-than-anticipated full-year revenue guidance, sparking concerns about its future growth and performance.
• The appointment of Zimmer Biomet's CFO to a new role at Incyte may have impacted investor sentiment, prompting questions on the company's financial decisions and overall strategy.
• Investors are keeping a close eye on Incyte's capacity to sustain revenue growth, introduce new products beyond Jakafi, and enhance profitability and shareholder value.

28.03.2026 - INCY Stock was down 2.2%

• Despite reporting strong financial results for Q1 2026, including surpassing earnings per share and revenue expectations, INCY's stock took a hit, falling nearly 4%.
• The bearish movement can be attributed to the company's full-year revenue guidance falling short of analyst projections by approximately $710 million, leading to investor concerns about future growth prospects.
• The departure of Zimmer Biomet's CFO to pursue another opportunity at Incyte might have also influenced market sentiment, raising questions about potential impacts on financial strategies and decision-making at INCY.
• The market's reaction indicates that while the company demonstrated solid performance in the first quarter, concerns about future revenue outlook and key executive transitions contributed to the bearish trend in INCY's stock price.

19.11.2025 - INCY Stock was up 5.0%

• The strong bullish movement in Incyte's stock today could be attributed to the positive quarterly results, beating analyst EPS and revenue estimates.
• The recent approval for Minjuvi in Europe, a chemotherapy-free immunotherapy for follicular lymphoma, has likely boosted investor confidence in Incyte's oncology portfolio.
• The significant insider selling by Incyte's EVP, Michael James Morrissey, might have initially raised concerns, but the overall market sentiment seems to have focused more on the company's recent achievements and future pipeline potential.
• Incyte's upcoming presentation at the J. P. Morgan Healthcare Conference could also be generating optimism among investors regarding the company's future outlook and growth prospects.

10.01.2026 - INCY Stock was down 7.0%

• Incyte Corporation's stock experienced a bearish movement after reporting mixed Q4 2025 results, with a revenue beat but an earnings miss.
• Despite strong sales growth, including significant increases in Jakafi and Opzelura sales, the company's adjusted EPS fell short of expectations due to higher operating expenses.
• The market reaction indicates that investors were more focused on the earnings miss rather than the revenue beat, leading to a decline in the stock price.
• Analysts maintaining a Hold rating on the stock and highlighting upcoming pipeline readouts and commercial execution as key focuses suggest a cautious outlook on the company's performance in 2026.

10.01.2026 - INCY Stock was down 6.0%

• INCY reported a Q4 profit miss despite strong sales growth, leading to a negative market movement.
• The stock declined in pre-market trading due to concerns about the earnings per share miss, although revenue surpassed expectations.
• A Hold rating on INCY stock was reiterated by Truist Securities, highlighting upcoming pipeline readouts and commercial execution as significant areas of focus for the company in 2026.
• The company's conservative 2026 revenue guidance and increased R&D and launch costs impacting profitability were factors contributing to the pessimistic outlook on the stock.

10.01.2026 - INCY Stock was down 5.3%

• Today, Incyte's stock (INCY) faced a bearish movement due to specific reasons:
• Despite surpassing revenue expectations for Q4 CY2025 at $1.51 billion, the company's non-GAAP profit of $1.80 per share fell short of analyst predictions, leading to investor dissatisfaction.
• The 2026 revenue forecast of $4.77 billion to $4.94 billion, which is conservative compared to current analyst consensus, along with heightened R&D and launch expenses affecting profitability, influenced the negative market outlook.
• Despite emphasizing significant core business growth and pipeline advancements, conflicting financial results and insider sales activity raised investor concerns and triggered a stock sell-off.
• Investors had anticipated more robust outcomes, especially in terms of profitability, resulting in a 4.4% pre-market trading decline.

06.00.2026 - INCY Stock was up 4.1%

• Positive top-line data from its Phase III frontMIND trial for tafasitamab in combination with lenalidomide and R-CHOP met primary and key secondary endpoints, boosting investor confidence in the company's pipeline.
• Plans to submit a supplemental biologics license application for tafasitamab as a first-line therapy for DLBCL in 2026 signify potential future revenue streams and market expansion for Incyte.
• Analysts' caution about market share due to competitive landscape may present challenges, but the strong trial results have the potential to reshape Incyte's investment narrative and reduce its reliance on existing products like Jakafi.
• Overall, positive trial outcomes and future regulatory filings have spurred investor optimism and contributed to the bullish movement in Incyte's stock today.

06.01.2026 - INCY Stock was up 5.0%

• Increase in price target for Incyte to $110 from $102, along with other analysts adjusting their targets, has created a positive outlook for the stock, leading to a bullish movement.
• Expectations of a strong Q4 earnings report, driven by robust sales of its key drugs and a high probability of an earnings beat, have likely contributed to investor optimism.
• The positive opinion from CHMP of the EMA for Incyte's Zynyz in treating a rare cancer indication opens up new market opportunities, further boosting investor confidence in the company's growth potential.
• The upcoming earnings call on February 10 to unveil Q4 and full-year 2025 results adds anticipation and excitement among investors, fueling the bullish sentiment towards Incyte's stock.

07.00.2026 - INCY Stock was up 5.2%

• Positive Phase III trial results for tafasitamab in combination with lenalidomide and R-CHOP for DLBCL have significantly boosted investor confidence in Incyte's potential for a new treatment option in the oncology space.
• Strategic collaborations and exclusive license agreements with Prelude Therapeutics have reshaped Incyte's pipeline, indicating a promising future for the company's oncology programs.
• Despite analyst caution regarding market share due to a competitive landscape, the successful trial outcomes and plans for regulatory approval have propelled INCY stock to gain traction among investors, leading to today's bullish market movement.
• Overall, the optimistic news surrounding Incyte's clinical developments and strategic partnerships have fueled positive sentiment and contributed to the stock's upward momentum.

29.03.2026 - INCY Stock was up 6.2%

• Bullish Movement: The recent notable uptrend in Incyte Corporation's stock price is a result of its strong Q1 2026 financial performance and optimistic projections for future expansion.
• Earnings Beat: Incyte reported a remarkable 20% year-over-year growth in net sales, propelled by strong product demand and significant progress in its pipeline, particularly evident through successful regulatory submissions and favorable trial outcomes.
• Investor Confidence: The company's disclosure of upcoming participation in investor conferences during May has contributed to enhancing investor trust in its strategic vision and dedication to sustained growth.
• Market Positioning: Despite facing competition in the market and the necessity for pipeline successes, Incyte's solid financial results and diverse product portfolio point towards a bright future outlook concerning its growth trajectory and market status.

08.00.2026 - INCY Stock was down 5.1%

• INCY stock experienced a strong bearish movement despite positive Phase 3 trial results for its lymphoma drug, Monjuvi/Minjuvi.
• The bearish movement could be attributed to profit-taking by investors after a significant run-up in the stock price following the positive trial results.
• The market may also be reacting to broader sector trends or macroeconomic factors impacting biotech stocks, leading to a temporary pullback in INCY's share price.
• It's essential for investors to consider the long-term growth potential of INCY, especially with promising developments in its pipeline and successful clinical trials, despite the short-term market volatility.